Latest News & Features
Big Pharma
A Federal Circuit decision provides lessons on why inaction over patent terms may risk incurable invalidation of important patents, writes Vincent Shier of Haynes Boone. 28 September 2023
Big Pharma
Examining a series of case studies, Takanori Abe of Abe & Partners provides an overview of lifecycle management failures and successes in regimen patents. 19 September 2023
Biotechnology
Although UK research universities were going strong after Horizon funding was pulled, it could have been a different story had the scheme not been reinstated, finds Sarah Speight. 14 September 2023
Big Pharma
Despite the shared language, there are tangible differences between the US, EU and UK standards, explain Jeffrey Lewis and Stuart Knight of Foley Hoag. 12 September 2023
Big Pharma
The news that the UK will rejoin the €95.5 billion research fund has been met with widespread relief, but it’s a bittersweet story, finds Sarah Speight. Reaction from CMS, Arnold & Porter, Bird & Bird, HGF. 7 September 2023
Biotechnology
Technology is continuing to transform women’s healthcare and female inventors are driving the change—but more needs to be done to ensure they secure IP rights. 7 September 2023
Big Pharma
Bernie Sanders’ plan to ‘delink’ the price of drugs from the cost of development ignores history, argue Andrei Iancu and David Kappos. 29 August 2023
Americas
A recent precedential case highlights the thorny issue of what constitutes a fair response to new claim constructions following an institution, says Blair Jacobs of McKool Smith. 17 August 2023
Big Pharma
This week marks the first anniversary of its enactment but the US Inflation Reduction Act still poses questions for pharmaceutical companies, say Alice Valder Curran and Cullen Taylor of Hogan Lovells. 15 August 2023
Big Pharma
Are we now seeing the power posed by the court as a litigation forum, asks Antje Brambrink of Finnegan. 15 August 2023